PTSM: Pharmaceutical Technology Sourcing and Management, May 4, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, May 4, 2011
APIs
Growth in the US Prescription Drug Market Slows
By Patricia Van Arnum
Volume growth in the US prescription drug market was at historically low levels in 2010, and revenue growth was anemic.
Outsourcing
A Hard Look at Third-Party External Supply Networks
By Gregg Brandyberry
The complexity of third-party external supply networks requires new ways to manage them.
Pharma Partner Focus
Spectrum Chemical Expands in China
By Patricia Van Arnum
Spectrum Chemical Mfg., a supplier of bulk fine chemicals and pharmaceutical ingredients, opens new facilities in China and augments its custom-synthesis business.
Sourcing
Innovation in the Pharma Supply Chain
By Patricia Van Arnum
An upcoming conference by the Drug, Chemical and Associated Technologies Association (DCAT) will focus on innovative practices and strategies for optimizing sourcing, procurement, and the management of the pharmaceutical supply chain.
CSR and Sustainability Forum
Distribution and Administration in Public Health, Government, and Developing World Markets
By Chan Harjivan , James Guyton
This article, which focuses on distribution and administration, is Part III of a three-part series on biopharmaceutical issues in public health, government, and developing-world markets.
GlaxoSmithKline and Singapore Partner in Green Manufacturing
By Patricia Van Arnum
GlaxoSmithKline and the Singapore Economic Development Board team in advancing sustainable pharmaceutical manufacturing.
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here